PRED FORTE (prednisolone acetate) by AbbVie is clinical pharmacology prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. First approved in 1973.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
PRED FORTE (prednisolone acetate) is a topical ophthalmic corticosteroid suspension approved in 1973 for anti-inflammatory treatment of the eye. It works by inhibiting edema, fibrin deposition, capillary dilation, and phagocytic migration, with 3-5 times the anti-inflammatory potency of hydrocortisone. The drug is used to treat inflammatory conditions of the anterior segment of the eye.
Product is approaching loss of exclusivity with modest Part D spending of $1M and 4,513 claims, suggesting a small but established patient population requiring defensive commercial strategy.
CLINICAL PHARMACOLOGY Prednisolone acetate is a glucocorticoid that, on the basis of weight, has 3 to 5 times the anti-inflammatory potency of hydrocortisone. Glucocorticoids inhibit the edema, fibrin deposition, capillary dilation, and phagocytic migration of the acute inflammatory response, as…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparison of 0.5% Loteprednol Etabonate Versus 1% Prednisolone Acetate Following Cataract Surgery
Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
Study of T-PRED(TM) Compared to Pred Forte(R) II
Study of T-PRED(TM) Compared to Pred Forte(R)
Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells
Worked on PRED FORTE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on PRED FORTE as an AbbVie brand offers exposure to ophthalmology market dynamics, managed care negotiations, and generic transition strategies in a specialized therapeutic area. This role is suited for professionals seeking stable, established product experience rather than launch or pipeline development opportunities.